Your browser's JavaScript is disabled.

To properly view the content on this page, please enable JavaScript.

Publications

Frontiers in Oncology

All Publications

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

Clinical Imetelstat: MF Imetelstat

Frontiers in Oncology

Olschok, et. al.